Aldara gets FDA nod for treatment of sBCC

Article

St. Paul, Minn. - Aldara (imiquimod) Cream 5 percent, a topical immune response modifier, has received U.S. Food and Drug Administration (FDA) approval for the treatment of superficial basal cell carcinoma (sBCC).

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.